Core Viewpoint - Actinium Pharmaceuticals has initiated the first clinical trial for Actimab-A under a Cooperative Research and Development Agreement with the National Cancer Institute, focusing on a triplet combination therapy for acute myeloid leukemia (AML) patients [1][2][3] Group 1: Clinical Trial Details - The trial (NCT06802523) will evaluate the combination of Actimab-A, Venetoclax, and ASTX-727 in frontline AML patients [1] - Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225, targeting CD33, which is expressed on myeloid blasts in AML [1] - The study aims to assess the rate and duration of Complete Remission (CR) and safety, including the optimal dose of Actimab-A [1] Group 2: Mechanism and Benefits - Actimab-A's mechanism is mutation agnostic, potentially improving outcomes for patients with high-risk features, such as TP53 mutations, where current therapies have limited success [2] - The triplet regimen can be administered conveniently in an outpatient setting, as both Venetoclax and ASTX-727 are oral agents [2] - Preclinical studies indicate that Actimab-A can synergize with Venetoclax by depleting MCL-1, which mediates resistance to Venetoclax [2] Group 3: Company Vision and Market Potential - The company anticipates 2025 to be a transformational year, aiming to establish Actimab-A as a backbone therapy for AML and other myeloid malignancies [3] - Actinium is focused on addressing the high unmet medical needs in AML, with over 100,000 patients in the U.S. and other major markets [3][5] - The triplet combination represents the first-ever use of targeted radiotherapy as a backbone therapy in AML, with initial clinical data expected in the second half of 2025 [5]

Group 1: Dividend Stocks Overview - Dividend stocks are perceived as stable and dependable, often associated with low-growth industries or mature companies [1] - Momentum stocks typically do not pay dividends as they reinvest capital for growth, but a combination of strong dividend yield and price momentum is favorable for investors [2] Group 2: Greystone Housing Impact Investors - Greystone Housing Impact Investors has a dividend yield of 11.94% and an annual dividend of $1.48, with a 3-year annualized dividend growth of 6.85% [3] - The company employs a hedging strategy to stabilize cash flows amid interest rate fluctuations, allowing it to maintain dividend payments despite a high payout ratio of 192.21% [3][5] - Greystone has formed a joint venture with BlackRock for construction lending, addressing gaps left by commercial banks [4] Group 3: TXO Partners - TXO Partners offers a dividend yield of 12.47% with an annual dividend of $2.32, but has a negative payout ratio of -39.06%, indicating potential challenges in sustaining dividends [7][8] - The stock has rebounded recently after a decline, with a notable increase of about 25% since mid-December [7] Group 4: Frontline - Frontline has a dividend yield of 4.93% and an annual dividend of $0.80, with a payout ratio of 36.04% [9] - Despite experiencing a 29% decline in shares, Frontline has seen a year-to-date rebound of over 9% [9] - Analysts have mixed opinions on Frontline, with a consensus Buy rating and a price target suggesting over 52% upside potential [10][11]

Financial Performance - The company reported a profit of $66.7 million, or $0.30 per share, for the fourth quarter of 2024, compared to a profit of $60.5 million in the previous quarter[4]. - Adjusted profit for the fourth quarter of 2024 was $45.1 million, down from $75.4 million in the previous quarter, primarily due to a decrease in TCE earnings from $292.2 million to $249.4 million[8]. - Reported revenues for the fourth quarter of 2024 were $425.6 million[4]. - The Company reported total revenues and other operating income of $2,162.5 million for the year ended December 31, 2024, compared to $1,826.3 million for the previous year, representing an increase of 18.4%[40]. - The profit for the period in the fourth quarter of 2024 was $118.4 million, a decrease of 0.2% from $118.4 million in the fourth quarter of 2023[40]. - Basic and diluted earnings per share for the year ended December 31, 2024, were $2.23, down from $2.95 in 2023, indicating a decrease of 24.3%[40]. - The Company reported a profit of $495,583 for FY 2024, compared to $656,414 in FY 2023, representing a decline of approximately 24.5%[43]. - Adjusted profit for FY 2024 was $396,642, down from $585,708 in FY 2023, indicating a decrease of about 32.2%[45]. - The adjusted basic and diluted earnings per share for FY 2024 were $1.78, down from $2.63 in FY 2023, a decrease of approximately 32.3%[45]. Cash Flow and Dividends - The company declared a cash dividend of $0.20 per share for the fourth quarter of 2024, with a record date of March 14, 2025[23]. - The company paid dividends totaling $434,115 in FY 2024, down from $638,928 in FY 2023, a reduction of about 32.1%[43]. - Net cash provided by operating activities for Q4 2024 was $167,848, a decrease from $100,494 in Q4 2023[42]. - The company reported cash and cash equivalents of $413.5 million as of December 31, 2024, an increase from $308.3 million as of December 31, 2023, representing a growth of 34.1%[41]. - Cash and cash equivalents at the end of Q4 2024 were $413,532, up from $308,322 at the end of Q4 2023, marking an increase of about 34.1%[42]. Fleet and Operational Metrics - As of December 31, 2024, the company's fleet consisted of 81 vessels with an aggregate capacity of approximately 17.8 million DWT, with an average age of 6.6 years[15]. - The current tanker orderbook for the asset classes owned by the company constitutes 18.4% of the existing global fleet, with most growth attributed to deliveries scheduled in 2026 and 2027[14]. - The number of contracted ballast days at the end of Q4 2024 was 1,116 days for VLCCs, indicating ongoing operational commitments[54]. - Spot days for VLCCs acquired from Euronav totaled 8,518 in Q4 2024, compared to just 184 in FY 2023, indicating enhanced fleet utilization[51]. Debt and Financing - The company entered into three senior secured credit facilities totaling up to $239.0 million to refinance existing debt and provide revolving credit capacity of up to $91.9 million[5]. - The Company entered into a senior secured credit facility of up to $72.3 million with Crédit Agricole in February 2025 to refinance outstanding debt and provide additional revolving credit capacity of up to $25.4 million[28]. - The Company also secured a credit facility of up to $47.0 million with SEB for refinancing debt on a Suezmax tanker, along with a revolving credit capacity of up to $14.9 million[29]. - The Company’s long-term debt as of December 31, 2024, was $3,284.1 million, compared to $3,194.5 million as of December 31, 2023, reflecting an increase of 2.8%[41]. Market and Economic Conditions - Global oil consumption averaged 103.4 million barrels per day in the fourth quarter of 2024, an increase of 1.0 mbpd compared to the same period last year[10]. - The company anticipates continued growth in TCE rates as market conditions improve and operational efficiencies are realized[54]. Time Charter Equivalent (TCE) Performance - Average daily spot TCE earnings for VLCCs, Suezmax tankers, and LR2/Aframax tankers were $35,900, $33,300, and $26,100, respectively, in the fourth quarter of 2024[4]. - Total Time Charter Equivalent (TCE) for FY 2024 was $1,269,031, an increase from $1,170,065 in FY 2023, reflecting a growth of approximately 8.4%[48]. - Total Time Charter Equivalent (TCE) for Q4 2024 was $1,269,031,000, a notable increase from $369,718,000 in Q4 2023, marking a growth of 243%[51]. - Total Spot TCE for Q4 2024 was $1,196,090,000, up from $355,661,000 in Q4 2023, reflecting a year-over-year growth of 236%[51]. - Spot TCE for VLCCs acquired from Euronav in Q4 2024 was $339,888,000, compared to $1,054,000 in FY 2023, indicating a substantial increase in revenue generation[51]. - Spot TCE per day for VLCCs acquired from Euronav in Q4 2024 was $39,900, compared to $5,700 in FY 2023, showcasing improved daily earnings[51]. - Suezmax TCE for Q4 2024 was $8,697,000, up from $0 in FY 2023, reflecting the introduction of new revenue streams[51].

Financial Data and Key Metrics Changes - In Q4 2024, Frontline reported a profit of $66.7 million or $0.30 per share, with an adjusted profit of $45.1 million or $0.20 per share, a decrease of about $30 million compared to the previous quarter primarily due to a decline in TCE earnings [11][12] - The company achieved TCE earnings of $35,900 per day for its VLCC fleet, $33,400 per day for Suezmax, and $26,100 per day for LR2/Aframax in Q4 2024 [2][8] - Strong liquidity was reported at $693 million in cash and cash equivalents, including undrawn credit facilities and marketable securities [12][13] Business Line Data and Key Metrics Changes - For Q1 2025, 80% of VLCC days are booked at $43,700 per day, 77% of Suezmax days at $35,400 per day, and 64% of LR2/Aframax days at $29,700 per day [3][8] - The average cash cost breakeven rates for 2025 are estimated at approximately $29,200 per day for VLCCs, $24,000 for Suezmax, and $22,200 for LR2 tankers, with a fleet average of about $26,200 per day [14] Market Data and Key Metrics Changes - Global oil consumption averaged 103.4 million barrels per day in Q4 2024, up 1 million barrels per day year-on-year, expected to reach 104.5 million barrels by year-end [18] - Global oil exports were down 700,000 barrels per day in Q4 2024, contributing to disappointing rates [19] - The average fleet size for tankers is currently 13.7 years, the highest since 2001, with 46% of vessels over 15 years old [21] Company Strategy and Development Direction - The company aims to maintain a focus on compliant tankers amidst geopolitical uncertainties and sanctions enforcement [7][17] - Frontline is cautious about newbuilding commitments, preferring to wait for clearer market signals before making significant investments [90][92] - The company emphasizes the importance of adapting trading patterns based on market conditions, preferring short-distance trades in a struggling market [102] Management's Comments on Operating Environment and Future Outlook - Management noted that the tanker market remains well-functioning despite geopolitical noise, with a belief in stable oil supply and demand [54][118] - The company anticipates that demand for compliant tonnage will grow, particularly as key Asian importers seek alternative supplies [55] - The management expressed concerns about the aging fleet and the potential for increased demand for compliant vessels if sanctions on Iranian oil are lifted [112] Other Important Information - The company has no newbuilding commitments and no significant debt maturities until 2028, allowing for a stable financial position [13] - The operational expenses for Q4 2024 were reported at $7,600 per day for VLCCs and $9,100 for Suezmax, with a fleet average OpEx of $7,400 excluding drydock [15] Q&A Session Summary Question: Update on geopolitical events and their impact on chartering - Management noted a significant change in chartering behavior following sanctions, with a spike in Aframax rates for compliant vessels [60] Question: Clarification on drydocks and administrative expenses - Management confirmed only three drydocks for 2025 and provided insights on normalized administrative expenses expected to be around $9 to $10 million per quarter [67][70] Question: Differences in earnings between Frontline and Euronav vessels - The spread was attributed to strategic trading decisions, with Frontline focusing on eco scrubber-fitted vessels for long voyages [82] Question: Capital deployment strategies amid aging fleet and slow newbuild deliveries - Management expressed a cautious approach to capital deployment, preferring to wait for market clarity before committing to new builds [90][92] Question: Strategy for forward booking in a volatile environment - Management emphasized the importance of keeping vessels in the spot market and adjusting trading patterns based on market conditions [102]

Group 1 - The presentation of Frontline plc's fourth quarter 2024 results is scheduled for a webcast/conference call on February 28, 2025, at 15:00 CET [1] - The information is subject to the disclosure requirements under the Norwegian Securities Trading Act [1]

Group 1 - Frontline plc is set to release its preliminary fourth quarter 2024 results on February 28, 2025, at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time) [1] - A webcast and conference call will be held for the results presentation, which will be available for download from the Investor Relations section of the company's website [1][2] - Participants can attend the conference call via a webcast link or by registering online for dial-in details [2]

Core Viewpoint - Frontline (FRO) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended December 2024, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for release on February 28, 2025, with a consensus EPS estimate of $0.20, reflecting a year-over-year decrease of 56.5%. Revenues are projected to be $266.87 million, which is a 3.9% increase from the previous year [3][2]. - The consensus EPS estimate has been revised down by 35.85% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate being the same as the consensus for Frontline, resulting in an Earnings ESP of 0% [10][11]. - Frontline currently holds a Zacks Rank of 1 (Strong Buy), but this combination makes it challenging to predict an earnings beat conclusively [11]. Historical Performance - In the last reported quarter, Frontline was expected to post earnings of $0.39 per share but only achieved $0.34, resulting in a surprise of -12.82%. The company has not surpassed consensus EPS estimates in any of the last four quarters [12][13]. Industry Context - EuroDry (EDRY), another player in the Zacks Transportation - Shipping industry, is expected to report earnings of $0.07 per share for the same quarter, indicating a year-over-year change of -110%. Revenues are expected to be $16.43 million, up 3.3% from the previous year [17]. - The consensus EPS estimate for EuroDry has been revised down by 553.1% over the last 30 days, and it also has an Earnings ESP of 0.00% combined with a Zacks Rank of 5 (Strong Sell), making it difficult to predict an earnings beat [18].

Core Insights - The TUS+VEN+AZA triplet therapy has shown promising early results in achieving complete remission in newly diagnosed acute myeloid leukemia (AML) patients, particularly those with TP53 mutations [1][3][4] - The therapy is being developed as a frontline treatment for diverse populations of newly diagnosed AML patients who are ineligible for induction chemotherapy [1][4][5] Group 1: Clinical Trial Results - The TUSCANY trial has reported complete remissions in Cycle 1 for patients with TP53 mutations and FLT3 wildtype AML [1][3][6] - Early data from the trial indicates favorable safety and antileukemic activity, with no dose-limiting toxicities observed in patients receiving the lowest dose of TUS (40 mg) [2][6] - The triplet therapy has demonstrated the ability to treat patients with traditionally difficult-to-treat mutations, improving patient outcomes from the outset [3][4] Group 2: Trial Design and Administration - The TUSCANY Phase 1/2 study is designed to test various doses and schedules of TUS in combination with standard dosing of azacitidine (AZA) and venetoclax (VEN) [5] - TUS will be administered as a once-daily oral agent in 28-day cycles, starting at a dose of 40 mg, with planned dose escalations after safety reviews [5] - The trial aims to enroll 18-24 patients by mid-late 2025, with data to be released as it becomes available [5] Group 3: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [8] - The company's lead clinical-stage oral kinase inhibitor, tuspetinib (TUS), has shown activity as both a monotherapy and in combination therapy for relapsed or refractory AML [8]

Core Points - The 2024 Annual General Meeting of Frontline plc was held on December 12, 2024, in Limassol, Cyprus, where the audited consolidated financial statements for the year ended December 31, 2023, were presented [1] Resolutions Passed - John Fredriksen was re-elected as a Director of the Company [2] - James O'Shaughnessy was re-elected as a Director of the Company [3] - Ola Lorentzon was re-elected as a Director of the Company [4] - Cato Stonex was re-elected as a Director of the Company [5] - Steen Jakobsen was re-elected as a Director of the Company [6] - Ørjan Svanevik was elected as a Director of the Company [7] - Dr. Maria Papakokkinou was elected as a Director of the Company [8] - PricewaterhouseCoopers of Limassol, Cyprus, was re-appointed as auditors, and the Directors were authorized to determine their remuneration [8] - The remuneration of the Company's Board of Directors was approved, not to exceed USD 600,000 for the year ended December 31, 2024 [8] Shareholder Rights Exclusion - The exclusion of shareholders' right of pre-emption for a maximum of 377,377,111 ordinary shares at a subscription price determined by the Board of Directors, not lower than USD 1 per share, was approved for twelve months starting from December 12, 2024 [9] - The exclusion of shareholders' right of pre-emption for a maximum of 377,377,111 debentures or other securities convertible into ordinary shares at a subscription price determined by the Board of Directors, not lower than USD 1 per security, was also approved for twelve months starting from December 12, 2024 [10] Remuneration Report - The Company's Remuneration Report for the year ended December 31, 2023, was approved on an advisory vote basis in accordance with the Encouragement of Long-Term Shareholders Engagement Law 111(I)/2021 [11]

Group 1 - Frontline plc (NYSE: FRO) reported Q3 2024 results, leading to a stock price drop to a 52-week low [1] - On the following Monday, the stock price continued to decline, reaching approximately $15.50 per share [1] - The oil tanker market is currently facing uncertainty regarding its future [1]